Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

The implementation of an inpatient continuous glucose ... and 43% used the FreeStyle Libre® 2. Of the 1506 attempted validations of CGM and fingerstick blood glucose tests, 87.8% met the ...

So, while you should always follow the fundamentals of healthy living – like exercising and eating a balanced diet – ...

The latest version of Abbott's FreeStyle Libre continuous glucose monitor is now available via the NHS to eligible people with diabetes in the UK. Abbott's wearable FreeStyle Libre 3 device ...

Foreign exchange fluctuation is a major headwind for ABT, as a considerable percentage of its revenues comes from outside the ...

Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetesWith a single sensor, the ...

Piper Sandler initiated coverage on Abbott Laboratories (NYSE: ABT) with an "overweight" rating and a price target of $131 ...

This page features the latest news about the Abbott Laboratories BDR share. Abbott FreeStyle Libre Continuous Glucose Monitoring Systems Obtain Significantly Expanded Coverage for Medicare ...

Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetes With a single sensor, the Eversense 365 system provides one year of use, versus ...

Just a few weeks after Dexcom’s Stelo became the first over-the-counter continuous glucose monitor (CGM ... the G7 and Libre 3 range. Analysts at William Blair said that with two devices ...